SynthesisAdvances in therapy2025
Meta-analysis to Investigate the Correlation Between Event-Free Survival and Overall Survival in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma.
Synthesis in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile overall survival (OS) is a widely accepted trial endpoint in oncology, survival data are often immature in early-stage populations. Alternative time-to-event outcomes have been considered by regulatory and reimbursement agencies to allow for early patient access. Event-free survival (EFS) has shown strong correlations with OS in patients with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) and within the subgroup with unresectable tumors. With novel neoadjuvant and adjuvant immunotherapies being investigated in resectable LA-HNSCC, this study aimed to assess the trial-level correlation of EFS and OS in patients with resectable LA-HNSCC.
methodsA systematic review (October 29, 2024) identified randomized controlled trials evaluating surgery with adjuvant therapy, neoadjuvant therapy, or both in patients with resectable LA-HNSCC. Trials reporting hazard ratios (HRs) or Kaplan-Meier curves for OS (time from randomization to death) and EFS (time from randomization to disease progression/recurrence or death) were eligible for the analysis. Base case included trials comparing neoadjuvant therapy + surgery + adjuvant therapy versus surgery + adjuvant therapy. Sensitivity analyses included models with trials comparing broader regimens (e.g., adjuvant therapy versus adjuvant therapy), excluding an outlier trial and restricting to publications after 2004. Correlations were measured between log(EFS HR) and log(OS HR) using regression models, with their strength measured using Pearson's correlation coefficient (R).
resultsThe review included 45 trials, with 20 trials qualifying for correlation analysis. R (95% confidence interval) was 0.91 (0.36, 0.99) in the base case (n = 5 trials) and 0.41 (-0.01, 0.71; n = 20), 0.78 (0.52, 0.91; n = 19), and 0.76 (0.41, 0.92; n = 13) in the three sensitivity analyses, respectively.
conclusionStrong trial-level correlations were observed between EFS and OS, suggesting EFS is a valid surrogate for OS in patients with resectable LA-HNSCC, particularly in trials investigating neoadjuvant therapy + surgery + adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.